Electrocardiogram Belt guidance for left ventricular lead placement and biventricular pacing optimization.


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
04 2023
Historique:
received: 21 09 2022
revised: 07 11 2022
accepted: 22 11 2022
medline: 3 4 2023
pubmed: 29 11 2022
entrez: 28 11 2022
Statut: ppublish

Résumé

Patients with ischemic cardiomyopathy, non-left bundle branch block, or QRS duration <150 ms have a lower response rate to cardiac resynchronization therapy (CRT) than did other indicated patients. The ECG Belt system (EBS) is a novel surface mapping system designed to measure electrical dyssynchrony via the standard deviation of the activation times of the left ventricle. The objectives of this study were to evaluate the efficacy of the EBS in patients less likely to respond to CRT and to determine whether EBS use in lead placement guidance and device programming was superior to standard CRT care. This was a prospective randomized trial of patients with heart failure and EBS-guided CRT implantation and programming vs standard CRT care. The primary end point was relative change in left ventricular end-systolic volume from baseline to 6 months postimplantation. A total of 408 patients from centers in Europe and North America were randomized. Although both patients with EBS and control patients had a mean improvement in left ventricular end-systolic volume, there was no significant difference in relative change from baseline (P = .26). While patients with a higher baseline standard deviation of the activation times derived greater left ventricular reverse remodeling, improvement in electrical dyssynchrony did not correlate with the extent of reverse remodeling. The findings of the present study do not support EBS-guided therapy for CRT management of heart failure with reduced ejection fraction.

Sections du résumé

BACKGROUND
Patients with ischemic cardiomyopathy, non-left bundle branch block, or QRS duration <150 ms have a lower response rate to cardiac resynchronization therapy (CRT) than did other indicated patients. The ECG Belt system (EBS) is a novel surface mapping system designed to measure electrical dyssynchrony via the standard deviation of the activation times of the left ventricle.
OBJECTIVES
The objectives of this study were to evaluate the efficacy of the EBS in patients less likely to respond to CRT and to determine whether EBS use in lead placement guidance and device programming was superior to standard CRT care.
METHODS
This was a prospective randomized trial of patients with heart failure and EBS-guided CRT implantation and programming vs standard CRT care. The primary end point was relative change in left ventricular end-systolic volume from baseline to 6 months postimplantation.
RESULTS
A total of 408 patients from centers in Europe and North America were randomized. Although both patients with EBS and control patients had a mean improvement in left ventricular end-systolic volume, there was no significant difference in relative change from baseline (P = .26). While patients with a higher baseline standard deviation of the activation times derived greater left ventricular reverse remodeling, improvement in electrical dyssynchrony did not correlate with the extent of reverse remodeling.
CONCLUSION
The findings of the present study do not support EBS-guided therapy for CRT management of heart failure with reduced ejection fraction.

Identifiants

pubmed: 36442824
pii: S1547-5271(22)02679-0
doi: 10.1016/j.hrthm.2022.11.015
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03504020']

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

537-544

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Auteurs

John Rickard (J)

Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: rickarj2@ccf.org.

Kevin Jackson (K)

Section of Cardiac Electrophysiology, Division of Cardiovascular Disease, Duke University Medical Center, Durham, North Carolina.

Michael Gold (M)

Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.

Mauro Biffi (M)

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Matteo Ziacchi (M)

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Joshua Silverstein (J)

Mount Carmel Health System, Columbus, Ohio.

Brian Ramza (B)

Division of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri.

Mark Metzl (M)

Department of Medicine, NorthShore University HealthSystem, Evanston, Illinois.

Eric Grubman (E)

Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut.

Richard Abben (R)

Cardiac Interventions and Cardiac Arrythmia Center, Cardiovascular Institute of the South, Houma, Louisiana.

Niraj Varma (N)

Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.

Ghiyath Tabbal (G)

Cardiac Interventions and Cardiac Arrythmia Center, Cardiovascular Institute of the South, Houma, Louisiana.

Cory Jensen (C)

Department of Cardiac Electrophysiology, Heartland Cardiology, Wichita, Kansas.

Griet Wouters (G)

Department of Cardiac Rhythm Management, Medtronic Inc., Mounds View, Minnesota.

Subham Ghosh (S)

Department of Cardiac Rhythm Management, Medtronic Inc., Maastricht, the Netherlands.

Kevin Vernooy (K)

Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH